- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01063556
Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.
May 13, 2013 updated by: Eisai Co., Ltd.
The purpose of this study is to investigate the pharmacokinetics of donepezil HCl 3 mg in subjects with end-state renal disease who were receiving haemodialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomised, single-center, open-label, single-dose, two-period crossover pharmacokinetics study of donepezil HCl tablets 3 mg in subjects receiving haemodialysis.
Subjects will be or will not be receiving haemodialysis.
After intervals of over 15 days, the subjects will be receiving the other treatment.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ibaraki
-
Moriya, Ibaraki, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
Subjects with end-stage renal disease who were receiving haemodialysis. Subject who are able and willing to give written informed consent.
Exclusion criteria:
Subjects with known hypersensitivity to drugs or foods. Subjects with a corrected QT interval greater than 450 msec at Screening period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Subjects will receive donepezil HCL 3 mg without haemodialysis.
After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
Subjects will receive donepezil HCl 3 mg with haemodialysis.
After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
|
Experimental: 2
|
Subjects will receive donepezil HCL 3 mg without haemodialysis.
After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
Subjects will receive donepezil HCl 3 mg with haemodialysis.
After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics parameter: maximum drug concentration in plasma
Time Frame: 0-48 hours
|
0-48 hours
|
Pharmacokinetics parameter: maximum drug concentration time in plasma
Time Frame: 0-48 hours
|
0-48 hours
|
Pharmacokinetics parameter: area under the plasma concentration time curve from Time 0 to 48.
Time Frame: 0-48 hours
|
0-48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Hirotake Ishigami, Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
February 1, 2010
First Submitted That Met QC Criteria
February 4, 2010
First Posted (Estimate)
February 5, 2010
Study Record Updates
Last Update Posted (Estimate)
May 14, 2013
Last Update Submitted That Met QC Criteria
May 13, 2013
Last Verified
November 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E2020-J081-107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on donepezil HCl
-
Eisai Korea Inc.CompletedAlzheimer's DiseaseKorea, Republic of
-
Eisai Inc.PfizerCompletedMild to Severe Alzheimer's DiseaseUnited States
-
University Health Network, TorontoEisai Inc.CompletedDementia Associated With Cerebrovascular DiseaseCanada
-
The Cleveland ClinicNational Institute on Aging (NIA)CompletedGenetic Risk for Alzheimer's DiseaseUnited States
-
Baylor College of MedicineAlbert Einstein Healthcare Network; Indiana University; Spaulding Rehabilitation... and other collaboratorsActive, not recruitingTraumatic Brain Injury | Memory DeficitsUnited States
-
Eisai Inc.PfizerCompleted
-
University of PittsburghNational Institute of Mental Health (NIMH)Completed
-
Whanin Pharmaceutical CompanyCompletedAlzheimer Type DementiaKorea, Republic of
-
Eisai Inc.Eisai LimitedCompleted
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan